The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care

Elliot B Tapper, Sumeet K Asrani, Elliot B Tapper, Sumeet K Asrani

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has shattered the meticulously developed processes by which we delivered quality care for patients with cirrhosis. Care has been transformed by the crisis, but enduring lessons have been learned. In this article, we review how COVID-19 will impact cirrhosis care. We describe how this impact unfolds over 3 waves; i) an intense period with prioritized high-acuity care with delayed elective procedures and routine care during physical distancing, ii) a challenging 'return to normal' following the end of physical distancing, with increased emergent decompensations, morbidity, and systems of care overwhelmed by the backlog of deferred care, and iii) a protracted period of suboptimal outcomes characterized by missed diagnoses, progressive disease and loss to follow-up. We outline the concrete steps required to preserve the quality of care provided to patients with cirrhosis. This includes an intensification of the preventative care provided to patients with compensated cirrhosis, proactive chronic disease management, robust telehealth programs, and a reorganization of care delivery to provide a full service of care with flexible clinical staffing. Managing the pandemic of a serious chronic disease in the midst of a global infectious pandemic is challenging. It is incumbent upon the entire healthcare establishment to be strong enough to weather the storm. Change is needed.

Keywords: Hepatic encephalopathy; Hepatocellular carcinoma; Liver disease; Telemedicine; Varices.

Conflict of interest statement

Conflict of interest Elliot Tapper has served as a consultant to Novartis, Kaleido, Axcella, and Allergan, has served on advisory boards for Mallinckrodt, Rebiotix, and Bausch Health, and has received unrestricted research grants from Gilead and Valeant. Please refer to the accompanying ICMJE disclosure forms for further details.

Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
The Impact of the COVID-19 pandemic unfolds in 3 waves. COVID-19, coronavirus disease 19; DDLT, deceased donor liver transplant; LDLT, living donor liver transplant.
Fig. 2
Fig. 2
Adaptations to preserve high quality care. (A) Interventions and (B) changes to program infrastructure. EMR, electronic medical record; ER, emergency room; EVL, endoscopic variceal ligation; PCP, primary care physician.

References

    1. Tapper E.B., Parikh N.D. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ. 2018;362:k2817.
    1. Asrani S.K., Devarbhavi H., Eaton J., Kamath P.S. Burden of liver diseases in the world. J Hepatol. 2019;70:151–171.
    1. Singal A.G., Mittal S., Yerokun O.A., Ahn C., Marrero J.A., Yopp A.C. Hepatocellular carcinoma screening associated with early tumor detection and improved survival among patients with cirrhosis in the US. Am J Med. 2017;130:1099–1106.e1.
    1. De Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752.
    1. Bass N.M., Mullen K.D., Sanyal A., Poordad F., Neff G., Leevy C.B. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–1081.
    1. Serper M., Kaplan D.E., Shults J., Reese P.P., Beste L.A., Taddei T.H. Quality measures, all-cause mortality, and health care use in a national cohort of veterans with cirrhosis. Hepatology. 2019;70:2062–2074.
    1. Tapper E.B., Hao S., Lin M., Mafi J.N., McCurdy H., Parikh N.D. The quality and outcomes of care provided to patients with cirrhosis by advanced practice providers. Hepatology. 2020;71:225–234.
    1. European Association for the Study of the Liver EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
    1. Kanwal F., Tapper E.B., Ho C., Asrani S.K., Ovchinsky N., Poterucha J. Development of quality measures in cirrhosis by the practice metrics Committee of the American association for the study of liver diseases. Hepatology. 2019;69:1787–1797.
    1. Rubin D. 2020. Three Waves of Illness from the COVID-19 Pandemic. Available at: . [Accessed 1 April 2020]
    1. Rich N.E., John B.V., Parikh N.D., Rowe I., Mehta N., Khatri G. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis. Hepatology. 2020 Epub ahead of print.
    1. Angelico R., Trapani S., Manzia T.M., Lombardini L., Tisone G., Cardillo M. The COVID-19 outbreak in Italy: initial implications for organ transplantation programs. Am J Transplant. 2020;20(7):1780–1784.
    1. Agarwal S.D., Pabo E., Rozenblum R., Sherritt K.M. Professional dissonance and burnout in primary care: a qualitative study. JAMA Intern Med. 2020;180:395–401.
    1. Villanueva C., Albillos A., Genescà J., Garcia-Pagan J.C., Calleja J.L., Aracil C. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597–1608.
    1. Caraceni P., Riggio O., Angeli P., Alessandria C., Neri S., Foschi F.G. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391:2417–2429.
    1. Ganapathy D., Acharya C., Lachar J., Patidar K., Sterling R.K., White M.B. The patient Buddy app can potentially prevent hepatic encephalopathy-related readmissions. Liver Int. 2017;37:1843–1851.
    1. Tapper E.B. Predicting overt hepatic encephalopathy for the population with cirrhosis. Hepatology. 2019;70:403–409.
    1. John B.V., Love E., Dahman B., Kurbanova N., Konjeti V.R., Sundaram L.T. Use of telehealth expedites evaluation and listing of patients referred for liver transplantation. Clin Gastroenterol Hepatol. 2020;18(8):1822–1830.e4.
    1. Konjeti V.R., Heuman D., Bajaj J.S., Gilles H., Fuchs M., Tarkington P. Telehealth-based evaluation identifies patients who are not candidates for liver transplantation. Clin Gastroenterol Hepatol. 2019;17:207–209.e1.
    1. Morando F., Maresio G., Piano S., Fasolato S., Cavallin M., Romano A. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol. 2013;59:257–264.
    1. Su G.L., Glass L., Tapper E.B., Van T., Waljee A.K., Sales A.E. Virtual consultations through the Veterans Administration SCAN-ECHO project improves survival for Veterans with liver disease. Hepatology. 2018;68:2317–2324.
    1. Cuadrado A., Llerena S., Cobo C., Pallás J.R., Mateo M., Cabezas J. Microenvironment eradication of hepatitis C: a novel treatment paradigm. Am J Gastroenterol. 2018;113:1639–1648.
    1. Cohen-Mekelburg S., Waljee A.K., Kenney B.C., Tapper E.B. Coordination of care associated with survival and healthcare utilization in a population-based study of patients with cirrhosis. Clin Gastroenterol Hepatol. 2020 Epub ahead of print.
    1. Kanwal F., Asch S.M., Kramer J.R., Cao Y., Asrani S., El-Serag H.B. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016;64:569–581.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren